For a more detailed review, Nagasaka and colleagues have recently published an article highlighting novel strategies to target KRAS beyond G12C inhibitors including cancer vaccines, adoptive cell therapy, PROTACs and CRISPR/Cas9 (60). Here, KRAS is linked to cancer.